Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A comprehensive review of key factors affecting the efficacy of antibody drug conjugate
Anupama Samantasinghar, Naina Sunildutt, Faheem Ahmed, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114408-114408
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 184
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 175
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Tribulations and future opportunities for artificial intelligence in precision medicine
Claudio Carini, Attila A. Seyhan
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 33
Standardizing digital biobanks: integrating imaging, genomic, and clinical data for precision medicine
Valentina Brancato, Giuseppina Esposito, Luigi Coppola, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer
Faheem Ahmed, Anupama Samantasinghar, Wajid Ali, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 17
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Syed Faheem Askari Rizvi, Lin‐Jie Zhang, Haixia Zhang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 309-334
Open Access | Times Cited: 17
A systematic review of computational approaches to understand cancer biology for informed drug repurposing
Faheem Ahmed, Anupama Samantasinghar, Afaque Manzoor Soomro, et al.
Journal of Biomedical Informatics (2023) Vol. 142, pp. 104373-104373
Open Access | Times Cited: 34
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 33
Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery
Naina Sunildutt, Pratibha Parihar, Abdul Rahim Chethikkattuveli Salih, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 30
Rational Identification of Novel Antibody‐Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors
Yu Guo, Zheyuan Shen, Wenbin Zhao, et al.
Advanced Science (2024) Vol. 11, Iss. 13
Open Access | Times Cited: 9
Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
Baochen Zhang, Mo Wang, Li Sun, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11469-11487
Closed Access | Times Cited: 8
Sulfur-containing marine natural products as leads for drug discovery and development
Feng-Wei Guo, Qun Zhang, Yu‐Cheng Gu, et al.
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102330-102330
Closed Access | Times Cited: 20
Network-based drug repurposing for HPV-associated cervical cancer
Faheem Ahmed, Young Jin Yang, Anupama Samantasinghar, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 5186-5200
Open Access | Times Cited: 18
Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments
Min Zhang, Fangxu Zhang, Jianfeng Wang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Youngbo Choi, Y. Choi, Surin Hong
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 221-221
Open Access | Times Cited: 6
Antibody drug conjugates in the clinic
Edidiong Udofa, Disha Sankholkar, Samir Mitragotri, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 6
Open Access | Times Cited: 6
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 6
Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
Ting-Lin Yang, Wenhui Li, Tao Huang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11903-11903
Open Access | Times Cited: 15
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
A New Age of Drug Delivery: A Comparative Perspective of Ferritin–Drug Conjugates (FDCs) and Antibody–Drug Conjugates (ADCs)
Juanji Hong, Kang Li, Jiuyang He, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1142-1147
Closed Access | Times Cited: 5
Half‐life extension of single‐domain antibody–drug conjugates by albumin binding moiety enhances antitumor efficacy
Quanxiao Li, Yu Kong, Yuxuan Zhong, et al.
MedComm (2024) Vol. 5, Iss. 5
Open Access | Times Cited: 4
Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis
Faheem Ahmed, Anupama Samantasinghar, Myung Ae Bae, et al.
ACS Omega (2024) Vol. 9, Iss. 27, pp. 29870-29883
Open Access | Times Cited: 4
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 4
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top